Adimanebart

阿地奈拜单抗

Report date: 2025/11/10 15:47:00

Base Information

Drug NameAdimanebart
Drug Alias NameARGX-119
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionMuscle, skeletal receptor tyrosine-protein kinase agonistsWnt signalling pathway modulators
TargetsMuscle, skeletal receptor tyrosine-protein kinase
Therapy Area/IndicationsMyasthenic Syndromes, CongenitalNeuromuscular DiseasesMuscular Atrophy, Spinal +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesArgenx Se
China Registration ClassN/A

Develop Information

Active CompaniesArgenx Se
Inactive CompaniesN/A
Active IndicationsMyasthenic Syndromes, CongenitalMuscular Atrophy, SpinalAmyotrophic Lateral Sclerosis
Inactive IndicationsNeuromuscular Diseases

Other Information

ATC CodeN/A
Related LinksN/A